EXPERIMENTAL MYASTHENIA GRAVIS
\ɛkspˌɛɹɪmˈɛntə͡l mˌa͡ɪɐsθˈiːni͡ə ɡɹˈavɪs], \ɛkspˌɛɹɪmˈɛntəl mˌaɪɐsθˈiːniə ɡɹˈavɪs], \ɛ_k_s_p_ˌɛ_ɹ_ɪ_m_ˈɛ_n_t_əl m_ˌaɪ__ɐ_s_θ_ˈiː_n_iə ɡ_ɹ_ˈa_v_ɪ_s]\
Sort: Oldest first
-
Any autoimmune animal disease model used in the study of MYASTHENIA GRAVIS. Injection with purified neuromuscular junction acetylcholine receptor (AChR) (see RECEPTORS, CHOLINERGIC) components results in a myasthenic syndrome that has acute and chronic phases. The motor endplate pathology, loss of acetylcholine receptors, presence of circulating anti-AChR antibodies, and electrophysiologic changes make this condition virtually identical to human myasthenia gravis. Passive transfer of AChR antibodies or lymphocytes from afflicted animals to normals induces passive transfer experimental autoimmune myasthenia gravis. (From Joynt, Clinical Neurology, 1997, Ch 54, p3)
By DataStellar Co., Ltd
Word of the day
Platidiam
- An inorganic water-soluble platinum complex. After undergoing hydrolysis, it reacts DNA produce both intra interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity cisplatin correlates with cellular arrest in G2 phase cell cycle.